Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

998
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
998
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

457
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
457
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

313
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
313
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

278
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zeitschrift fur Gastroenterologie·2022
Same author

Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults.

Clinical nutrition (Edinburgh, Scotland)·2021
Same author

[Drug-induced liver injury-significance of pathology].

Der Pathologe·2020
Same author

Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis.

Journal of proteomics·2019
Same author

Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.

Journal of cancer research and clinical oncology·2018
Same author

Editorial: HBeAg seroconversion is not sufficient to allow cessation of nucleos(t)ide analogue treatment in Caucasian hepatitis B patients.

Alimentary pharmacology & therapeutics·2018

Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

8.8K

[Hepatic steatosis : Differential diagnostics and current aspects].

A Canbay1, G Gerken1, L P Bechmann2

  • 1Klinik für Gastroenterologie und Hepatologie, Hufelandstr. 55, 45122, Essen, Deutschland.

Der Internist
|August 12, 2016
PubMed
Summary

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are rising, impacting liver transplantation rates. This review covers causes, diagnosis, and treatments for various hepatic steatosis forms.

Keywords:
Alcoholic steatohepatitisCarcinoma, hepatocellularLiver cirrhosisNon-alcoholic fatty liver diseaseSteatohepatitis

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.6K

Related Experiment Videos

Last Updated: Mar 16, 2026

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

8.8K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.6K

Area of Science:

  • Hepatology
  • Gastroenterology
  • Metabolic Diseases

Background:

  • Non-alcoholic fatty liver disease (NAFLD) prevalence is increasing globally, paralleling metabolic syndrome.
  • Obesity and type 2 diabetes are driving an expected rise in non-alcoholic steatohepatitis (NASH).
  • Alcoholic steatohepatitis (ASH) cirrhosis is a leading cause of liver transplantation (LTX) in Germany, with a significant HCC risk.

Purpose of the Study:

  • To discuss the causes of hepatic steatosis.
  • To outline diagnostic methods for hepatic steatosis.
  • To explore novel therapeutic approaches for various forms of steatosis.

Main Methods:

  • Literature review of causes, diagnostics, and treatments for hepatic steatosis.
  • Analysis of current trends in liver transplantation related to steatohepatitis.
  • Discussion of emerging therapeutic strategies.

Main Results:

  • NAFLD and NASH are increasingly significant causes of liver disease and indications for LTX.
  • ASH cirrhosis remains a primary indication for LTX in Germany.
  • Chemotherapy-associated steatohepatitis (CASH) is a less common cause of hepatic steatosis.

Conclusions:

  • Hepatic steatosis, particularly NASH, presents a growing challenge requiring effective management.
  • Early diagnosis and novel therapies are crucial for improving outcomes in patients with hepatic steatosis.
  • Understanding the diverse etiologies of hepatic steatosis is key to developing targeted treatments.